| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | — | — | — | — | — | — |
| 3d | — | — | — | — | — | — |
| 1w | — | — | — | — | — | — |
| 1m | — | — | — | — | — | — |
| 3m | — | — | — | — | — | — |
| 6m | — | — | — | — | — | — |
| 1y | — | — | — | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
iHuman trades at $1.20 but holds ~$3.20 per share in net cash alone, with operational value on top. The author applies DCF valuation to argue intrinsic value substantially exceeds current price, and expects the company to enter a new long-term growth phase, positioning it as a major return opportunity in the next 12 months.
DCF valuation shows significant upside potential for this cash-rich company trading at $1.37, well below intrinsic value. With recent entry into a long-term growth phase and improving operating prospects, the stock is undervalued relative to its asset base and future earnings power.
End of results.